Chana Fuchs

Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101.

Chana Fuchs, Jennifer Tepper, Donna Niedzwiecki et al. · Journal of Clinical Oncology · 2011 · 106 citations

Medicine, Oncology, Radiation Oncology +17

U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens

Ruthann M. Giusti, Kaushikkumar A. Shastri, Anne M. Pilaro et al. · Clinical Cancer Research · 2008 · 92 citations · Full text

Medicine, Oncology, Pharmacology +17

Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer

Martin H. Cohen, Huanyu Chen, Stacy S. Shord et al. · The Oncologist · 2013 · 59 citations · Full text

Medicine, Oncology, Pharmacology +12

FDA's Approval of the First Biosimilar to Bevacizumab

Sandra J. Casak, Steven J. Lemery, Jee Young Chung et al. · Clinical Cancer Research · 2018 · 36 citations

Pharmacy, Oncology, Pharmacokinetics +17

Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients >65 years compared with those ≤65: The BICC-C study

José Barrueco, J. Marshall, E. Mitchell et al. · Journal of Clinical Oncology · 2007 · 10 citations

Medicine, Pharmacology, Pharmacotherapy +10